William Blair & Company
IRD

William Blair & Company’s Opus Genetics IRD Stock Holding History

William Blair & Company’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,466
Closed -$56.7K – 2078
2026
Q1 		$56.7K Sell
12,466
-15,000
-55% -$51.9K ﹤0.01% 1682
2025
Q4 		$55.2K Buy
27,466
+3,000
+12% +$6.09K ﹤0.01% 1646
2025
Q3 		$40.4K Hold
24,466
– – ﹤0.01% 1665
2025
Q2 		$23K Hold
24,466
– – ﹤0.01% 1669
2025
Q1 		$24K Sell
24,466
-8,801
-26% -$9.83K ﹤0.01% 1651
2024
Q4 		$39.6K Hold
33,267
– – ﹤0.01% 1632
2024
Q3 		$43.6K Hold
33,267
– – ﹤0.01% 1648
2024
Q2 		$50.9K Hold
33,267
– – ﹤0.01% 1597
2024
Q1 		$66.9K Hold
33,267
– – ﹤0.01% 1566
2023
Q4 		$100K Hold
33,267
– – ﹤0.01% 1505
2023
Q3 		$111K Hold
33,267
– – ﹤0.01% 1490
2023
Q2 		$144K Buy
+33,267
New +$158K ﹤0.01% 1463

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

William Blair & Company's IRD Position: Q2 2026 in Review

William Blair & Company sold out of Opus Genetics (IRD) in Q2 2026, closing a stake of 12,466 shares — an estimated $56.7K sold.

William Blair & Company first reported a position in IRD in Q2 2023 and held it in 12 quarters. The position peaked at $144K in Q2 2023. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • William Blair & Company reported no remaining Opus Genetics position as of Q2 2026 after selling out during the quarter.
  • William Blair & Company sold 12,466 Opus Genetics shares in Q2 2026, an estimated $56.7K.
  • William Blair & Company first reported a position in Opus Genetics in Q2 2023 and held it in 12 quarters.
  • William Blair & Company's Opus Genetics position peaked at $144K in Q2 2023.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.